The aim of the study was to investigate the effects of the potent P‐gp inhibitor ciclosporin and its combination with the moderate CYP3A inhibitor fluconazole on rivaroxaban pharmacokinetics and on CYP3A activity. Study used MassTox Immunosuppressants for ciclosporine analysis.
Oral administration of CsA is safe, less time-consuming and economically advantageous. Close monitoring of CsA concentration is important, that has been performed with MassTox Immunosuppressants assay.
The comparison of patient data between LC/MS/MS and up‐dated immunoassays shows that a significant discrepancy still exists, especially for CSA and SIRO, confirming the greater specificity associated with use of the LC/MS/MS, measured with the OneMinute assay from Chromsystems
The sample prep of Chromsystems yields considerable cleaner extracts for cyclosporine in comparison to an in-house method
Please find here publications as guides for reference ranges or therapeutic ranges. As they may differ from other published data. Data vary depending on patient population and measurement method, please determine ranges for your laboratory. When determining ranges make sure that you comply with local national requirements.